Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Lilly To Seek EUA For Olumiant

Plus: Gilead Agrees European Procurement Deal On Veklury

Executive Summary

Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.

You may also be interested in...



Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data

Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.

Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.

Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel